Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. news centers on the company's completed plan of arrangement, under which XenoTherapeutics acquired all issued and outstanding common shares, and the related removal of ESSA common stock from Nasdaq listing and Section 12(b) registration. Recurring updates also address shareholder voting matters, material agreements, common-share, option and warrant disclosures, governance, risk factors, clinical or regulatory disclosures, and operating and financial results.
ESSA Pharma (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on prostate cancer therapies, reported its financial results for the second fiscal quarter ending March 31, 2024. Highlights include the promising Phase 1 data for masofaniten plus enzalutamide, showing a deep and durable reduction in PSA levels among mCRPC patients. Key achievements include 81% of patients achieving PSA90. ESSA forecasts the completion of Phase 2 enrollment by 1Q25, with preliminary data expected in mid-2025. Financially, ESSA experienced a net loss of $9.0 million, up from $7.1 million the previous year, due to increased R&D and G&A expenses. The company holds $135.9 million in cash reserves, enough to fund operations beyond 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.